Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

As Deadliest Strain Ravages Country, Four Experimental Ebola Vaccines to Be Deployed in the Congo

As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials took four experimental vaccines to the front lines and began to administer it to patients who may have been exposed to the deadly virus.

Read More »

Amarin Plans to Seek FDA Approval for CV Indication for Fish Oil Drug

Clinical data for a fish-oil-based drug from Amarin Corporation confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.

Read More »

AstraZeneca’s Farxiga curbs heart failure, kidney risks

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

Read More »

Lilly scraps a BACE program for Alzheimer’s

Eli Lilly scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s.

Read More »

Endo targets 2020 for launch of cellulite treatment

Endo International Plc expects to launch the company’s treatment for cellulite in the second half of 2020, a day after announcing results from two late-stage trials testing the drug.

Read More »

Foamix’s treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.

Read More »

Aveo’s RCC Drug Hits Mark in Phase III Trial

Aveo Oncology’s Phase III study of tivozanib for highly refractory advanced or metastatic renal cell carcinoma (RCC) met the primary endpoint of demonstrating a statistically significant benefit in PFS.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Llama Antibody Could Be The Key To Universal Flu Vaccine

New research indicates that llamas may hold the key to flu vaccines.

Read More »

AbbVie, Roche combo treatment meets main goal of leukemia trial

AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom